Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression

PurposeThe Dermatology Life Quality Index (DLQI) and the European Quality of Life-5 Dimension (EQ-5D) are separate measures that may be used to gather health-related quality of life (HRQoL) information from patients. The EQ-5D is a generic measure from which health utility estimates can be derived, whereas the DLQI is a specialty-specific measure to assess HRQoL. To reduce the burden of multiple measures being administered and to enable a more disease-specific calculation of health utility estimates, we explored an established mathematical technique known as ordinal logistic regression (OLR) to develop an appropriate model to map DLQI data to EQ-5D-based health utility estimates.MethodsRetrospective data from 4010 patients were randomly divided five times into two groups for the derivation and testing of the mapping model. Split-half cross-validation was utilized resulting in a total of ten ordinal logistic regression models for each of the five EQ-5D dimensions against age, sex, and all ten items of the DLQI. Using Monte Carlo simulation, predicted health utility estimates were derived and compared against those observed. This method was repeated for both OLR and a previously tested mapping methodology based on linear regression.ResultsThe model was shown to be highly predictive and its repeated fitting demonstrated a stable model using OLR as well as linear regression. The mean differences between OLR-predicted health utility estimates and observed health utility estimates ranged from 0.0024 to 0.0239 across the ten modeling exercises, with an average overall difference of 0.0120 (a 1.6% underestimate, not of clinical importance).ConclusionsThis modeling framework developed in this study will enable researchers to calculate EQ-5D health utility estimates from a specialty-specific study population, reducing patient and economic burden.

[1]  A. Kasuya EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[2]  T. Kohlmann,et al.  Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  Mayte Suárez-Fariñas,et al.  Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept , 2010, BMC dermatology.

[4]  G. Guyatt Commentary on Jack Dowie, "Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions". , 2002, Health economics.

[5]  A. Finlay,et al.  The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results , 2008, The British journal of dermatology.

[6]  Jack Dowie,et al.  Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions. , 2002, Health economics.

[7]  M. Augustin,et al.  Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities , 2013, Archives of Dermatological Research.

[8]  M. Radtke,et al.  Willingness‐to‐pay and quality of life in patients with vitiligo , 2009, The British journal of dermatology.

[9]  P. Reeves,et al.  Economic evaluation of etanercept in the management of chronic plaque psoriasis , 2009, The British journal of dermatology.

[10]  M. Sculpher,et al.  Alitretinoin for Severe Chronic Hand Eczema , 2012, PharmacoEconomics.

[11]  Å. Svensson,et al.  Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis. , 2011, Acta dermato-venereologica.

[12]  L. Misery,et al.  The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries , 2014, The Journal of investigative dermatology.

[13]  J. Schmitt,et al.  Correlation between Dermatology Life Quality Index (DLQI) scores and Work Limitations Questionnaire (WLQ) allows the calculation of percent work productivity loss in patients with psoriasis , 2015, Archives of Dermatological Research.

[14]  U. Persson,et al.  Analysis of three outcome measures in moderate to severe psoriasis: a registry‐based study of 2450 patients , 2012, The British journal of dermatology.

[15]  A. Williams EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[16]  N. Ikegami,et al.  Estimating an EQ-5D population value set: the case of Japan. , 2002, Health economics.

[17]  J. Habbema,et al.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. , 2001, Journal of clinical epidemiology.

[18]  R. Shikiar,et al.  Adalimumab treatment is associated with improvement in health‐related quality of life in psoriasis: Patient‐reported outcomes from a Phase II randomized controlled trial , 2007, The Journal of dermatological treatment.

[19]  J. Newton,et al.  Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. , 2000, Journal of the American Academy of Dermatology.

[20]  T. Szucs,et al.  Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema - a long-term analysis from a Swiss perspective , 2010, BMC dermatology.

[21]  G. Jemec,et al.  A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values , 2015, Patient related outcome measures.

[22]  M. Chren,et al.  Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis , 2006, The British journal of dermatology.

[23]  M. Ruggeri,et al.  The minimum clinically important difference for EQ-5D index: a critical review , 2014, Expert review of pharmacoeconomics & outcomes research.

[24]  Oliver Rivero-Arias,et al.  Mapping the Modified Rankin Scale (mRS) Measurement into the Generic EuroQol (EQ-5D) Health Outcome , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[26]  J. Szepietowski,et al.  Psychophysical aspects of hidradenitis suppurativa. , 2010, Acta dermato-venereologica.

[27]  Oliver Rivero-Arias,et al.  Estimating the Association between SF-12 Responses and EQ-5D Utility Values by Response Mapping , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  B. Monz,et al.  Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? , 2006, Chest.

[29]  A. Finlay,et al.  The Role of the EQ-5D in the Economic Evaluation of Dermatological Conditions and Therapies , 2012, Dermatology.

[30]  A. Finlay,et al.  A systematic review of the use of quality‐of‐life instruments in randomized controlled trials for psoriasis , 2017, The British journal of dermatology.

[31]  R. Doughty,et al.  Measuring health-related quality of life. , 1999, The New Zealand medical journal.

[32]  Leonie Segal,et al.  Comparing the Incomparable? A Systematic Review of Competing Techniques for Converting Descriptive Measures of Health Status into QALY-Weights , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.